How Weight-Loss Drugs Are Reshaping the Economy Before AI

While tech market valuations have heavily priced in anticipated AI efficiency, weight-loss medications are already changing physical consumption patterns and grocery sales.

Economic impact and market penetration

According to Goldman Sachs analysts, GLP-1 medications are projected to deliver a 1 percent lift to United States gross domestic product through direct productivity gains and health-related cost savings. In the United States, up to 18 percent of adults now use GLP-1 drugs, affecting more than 20 percent of households, as reported.

In New Zealand, uptake has accelerated despite a lack of public funding. Wegovy became available commercially in June 2025, and approximately 18,000 New Zealanders received prescriptions within the opening months. By early 2026, user numbers reached an estimated 50,000. Because users pay entirely out of pocket, current consumers are predominantly urban and higher-income—precisely the demographic targeted by domestic retail and hospitality sectors.

Shifts in grocery and export markets

A Cornell University study published in January 2026 found that affected households cut grocery spending by approximately 5 percent within six months, registering the steepest declines in processed goods, sugary drinks, and high-fat items. Conversely, supermarkets report rising demand for high-protein alternatives like Greek yogurt and cottage cheese.

For New Zealand’s export-driven economy, this behavioral shift creates distinct challenges and opportunities. New Zealand Trade and Enterprise (NZTE) exporter analysis cited by the New Zealand Herald places baked goods, confectionery, sweet and salty snacks, and sugary drinks under structural pressure, while fresh produce, seafood, lean meat, and high-protein dairy products experience growing demand. ASB chief economist Nick Tuffley noted in January 2026 that New Zealand food exporters largely supply foundational ingredients rather than direct-to-consumer items, providing a buffer that remains finite if global appetite for calorie-dense commodities softens.

Labor market participation

Beyond consumer goods, weight-loss treatments are influencing labor force metrics. Research by Harvard economist Rebecca Diamond, published as a National Bureau of Economic Research working paper, demonstrated that unemployed women increased their probability of securing employment by 26.9 percentage points after roughly 18 months on GLP-1 medications compared to a control group, primarily driven by improvements at the interview stage rather than on-the-job productivity.

This dynamic intersects with domestic labor forecasts. Neither Treasury’s May 2026 Budget projections—which forecast private consumption growth rising from 1.0 percent in 2026 to 3.0 percent thereafter—nor official labor models currently incorporate assumptions regarding GLP-1 participation shifts.

Fiscal pressure on public health funding

While economic analyses focus on productivity and retail adjustments, public healthcare systems face immediate financial exposure. In the United Kingdom, Mounjaro became the single most expensive medication in National Health Service history within one year of a wider rollout, reaching NZ$1.3 billion in spending during the 2025–26 period despite covering only 1 percent of eligible patients.

In New Zealand, hundreds of thousands of individuals meet clinical criteria for treatment. Pharmac has placed Wegovy on its Options for Investment list but has not issued a funding decision, leaving potential public health liabilities absent from official budget frameworks as prescription volumes continue to rise.